QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:EOLS

Evolus Stock Forecast, Price & News

$5.83
+0.18 (+3.19 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.45
Now: $5.83
$5.88
50-Day Range
$3.20
MA: $3.91
$5.65
52-Week Range
$2.85
Now: $5.83
$11.73
Volume423,909 shs
Average Volume892,918 shs
Market Capitalization$196.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.69
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Evolus logo

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

530th out of 1,480 stocks

Pharmaceutical Preparations Industry

274th out of 612 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555
Employees125

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share

Profitability

Net Income$-90,030,000.00
Net Margins-120.63%

Miscellaneous

Market Cap$196.76 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$5.83
+0.18 (+3.19 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evolus (NASDAQ:EOLS) Frequently Asked Questions

How has Evolus' stock price been impacted by Coronavirus?

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EOLS stock has decreased by 1.4% and is now trading at $5.83.
View which stocks have been most impacted by COVID-19
.

Is Evolus a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Evolus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EOLS, but not buy additional shares or sell existing shares.
View analyst ratings for Evolus
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Evolus?

Wall Street analysts have given Evolus a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evolus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Evolus
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings results on Thursday, October, 29th. The company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.06. The firm had revenue of $17.66 million for the quarter, compared to the consensus estimate of $12.40 million. Evolus had a negative return on equity of 121.11% and a negative net margin of 120.63%.
View Evolus' earnings history
.

What price target have analysts set for EOLS?

7 Wall Street analysts have issued twelve-month price objectives for Evolus' shares. Their forecasts range from $4.00 to $25.00. On average, they expect Evolus' share price to reach $9.43 in the next year. This suggests a possible upside of 61.7% from the stock's current price.
View analysts' price targets for Evolus
or view Wall Street analyst' top-rated stocks.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 42, Pay $1.11M)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 62, Pay $600.2k)
  • Dr. Rui Avelar Dip.SportMed, M.D., C.CFP, Chief Medical Officer and Head of R&D (Age 58, Pay $1.28M)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury
  • Mr. Jeffrey J. Plumer, Gen. Counsel
  • Ms. Crystal Muilenburg, VP of Corp. Communications & PR
  • Mr. Kurt Knab, VP of Sales
  • Ms. Dianne Whitfield, VP of HR
  • Mr. Michael Mazen Jafar, Chief Commercial Officer (Age 39)

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $5.83.

How big of a company is Evolus?

Evolus has a market capitalization of $196.76 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 125 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.